galantamine, Razadyne, Razadyne ER

Omudhome Ogbru, PharmD

Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

Jay W. Marks, MD

Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

GENERIC NAME: galantamine

BRAND NAME: Razadyne, Razadyne ER

DRUG CLASS AND MECHANISM: Galantamine is an oral medication used to
treat patients with Alzheimer's disease. Galantamine is in a class of drugs
called cholinesterase inhibitors that also includes tacrine (Cognex),
donezepil
(Aricept), and
rivastigmine (Exelon). Cholinesterase inhibitors inhibit (block)
the action of acetylcholinesterase, the enzyme responsible for the destruction
of acetylcholine. Acetylcholine is one of several neurotransmitters in the
brain, chemicals that nerve cells use to communicate with one another. Reduced
levels of acetylcholine in the brain are believed to be responsible for some of
the symptoms of Alzheimer's disease. By blocking the enzyme that destroys
acetylcholine, galantamine increases the concentration of acetylcholine in the
brain, and this increase is believed to be responsible for the improvement in
thinking. Galantamine was approved by the FDA in 2001. (The brand name of
galantamine was changed in 2005 from Reminyl to Razadyne.)